Sugi Predict

Sugi Predict / Compounds / SCHEMBL184869

SCHEMBL184869

SCHEMBL184869

Nc1ncc(N2CCOCC2)s1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.53
▸ PIK3CA P42336 9/20 0.44
▸ PIK3C3 Q8NEB9 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ PIK3R1 P27986 4/20 0.41
▸ MTOR P42345 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ AR P10275 1/20 0.41
▸ UCHL1 P09936 1/20 0.40
▸ PIK3CD O00329 2/20 0.39
▸ PIK3CB P42338 2/20 0.39
▸ LGMN Q99538 1/20 0.39
▸ CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154235 0.82 ALDH1A1 (0.42) GAAMAPTALOX15
SCHEMBL15522284 0.81 GAA (0.46) GAAKDM4ENPC1MAPTRAB9A
SCHEMBL19553269 0.79 AR (0.42) KDM4ESMN1; SMN2NPC1MAPTRAB9A
SCHEMBL31420231 0.79 USP2 (0.41) GAAPIK3CAKDM4ESMN1; SMN2POLB
SCHEMBL28418430 0.78 AR (0.41) GAAPIK3CAKDM4ESMN1; SMN2NPC1
SCHEMBL998557 0.78 HRH4 (0.45) GAAKDM4ESMN1; SMN2MAPT
SCHEMBL13271393 0.78 AR (0.41) GAAPIK3CAKDM4ESMN1; SMN2NPC1
SCHEMBL16002359 0.78 DPP4 (0.41) GAAPIK3CAKDM4ESMN1; SMN2MAPT
SCHEMBL20582980 0.76 HRH3 (0.42) GAAKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL14376256 0.76 PRKDC (0.43) GAAPIK3CAKDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
US-20230399312-A1 SUBSTITUTED PYRIMIDINES AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-12-14 — — US disclosed
US-20230399312-A1 SUBSTITUTED PYRIMIDINES AND METHODS OF USE THERAVANCE BIOPHARMA R&D IP LLC (US) 2023-12-14 — — US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 — — CN disclosed
US-11673879-B2 Substituted pyrimidines and methods of use THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-06-13 — — US disclosed
US-11673879-B2 Substituted pyrimidines and methods of use THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-06-13 — — US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 — — US disclosed
EP-4019515-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Dana-Farber Cancer Institute, Inc. (US) 2022-06-29 — — EP disclosed
US-20220055998-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-24 — — US disclosed
CN-101541811-A Pyrazolopyrimidine Derivatives DAIICHI SANKYO CO LTD (JP) 2009-09-23 — — CN disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 — — US disclosed
EP-2065388-A1 PYRAZOLOPYRIMIDINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-06-03 — — EP disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 — — US disclosed
EP-1963313-A2 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) F.HOFFMANN-LA ROCHE AG (CH) 2008-09-03 — — EP disclosed
WO-2007060140-A2 INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 — — WO disclosed
WO-2007060140-A2 INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 — — WO disclosed
US-20070123504-A1 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. 2007-05-31 — — US disclosed
US-20070123504-A1 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. 2007-05-31 — — US disclosed
US-20070123504-A1 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. 2007-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 GAA 203/4885PIK3CA 2230/4885PIK3C3 853/4885
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 GAA 455/4885PIK3CA 2987/4885PIK3C3 1174/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 GAA 455/4885PIK3CA 2987/4885PIK3C3 1174/4885
US-20070123504-A1 Diacylglycerol acyltransferase inhibitors DGAT2, DGAT1, LCAT GAA 200/4885PIK3CA 443/4885PIK3C3 1400/4885
US-20220055998-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK1, CDK13, CDK3 GAA 4372/4885PIK3CA 460/4885PIK3C3 189/4885
US-11673879-B2 Substituted pyrimidines and methods of use ALK, TYMP, ENTPD5 GAA 894/4885PIK3CA 600/4885PIK3C3 479/4885
US-20230399312-A1 SUBSTITUTED PYRIMIDINES AND METHODS OF USE ALK, TYMP, ENTPD5 GAA 894/4885PIK3CA 600/4885PIK3C3 479/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 GAA 402/4885PIK3CA 3182/4885PIK3C3 1719/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 GAA 203/4885PIK3CA 2230/4885PIK3C3 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.